The drugmaker has a golden window of opportunity to gain traction in the lucrative therapeutic field of Multiple Sclerosis
Novartis AG (ADR) (NYSE:NVS) investigational molecule for the treatment and management of multiple sclerosis has shown remarkable reduction in the disease progression up to 21%. The investigational molecule also aid in the reduction of the relapsing of the disease in comparison to the placebo with the change in the brain volume and volume of the lesions in the brain.
Siponimod will be available in the oral formulation and is expected to be the blockbuster drug as compared to other formulations available in the market due to its vital role in minimizing the disease progression. The investigational molecule has met the primary endpoints in the phase 3 study.
On the other hand, Roche is also working to make its place in the lucrative market of Multiple sclerosis. Its investigational molecule Ocrevus has shown its vitality and effectiveness in the management of relapsing-remitting MS and primary progressive MS. The drug has an added advantaged that till date no other drug is indicated in this condition and if approved, it will clinch the entire therapeutic market.
According to the analysts, the role of BAF312 is vital, as Novartis is going through an era of difficulties due to the slow growth of its highly expected drug Entresto for the treatment of heart failure. Alcon ophthalmology segment shows a sluggish growth. Siponimod sales will be a bit low due to the presence of Novartis Gilenya, which covers 80% of the MS patients and Siponimod will patch up 20% of the patients with an expected revenue generation of $1 billion annually, according to Berenberg Bank report.
Multiple sclerosis is a debilitating disease that is directly affecting the central nervous system impacting the normal functions of the brain, spinal cord, and other vital organs. This disease affects approximately 2.3 million people. Till date, there is no drug in the market that completely provide cure for the disease, but drugs are available which aid in the slowing the disease.